[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356195-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356195-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","differential-clinical-outcomes-of-palliative-radiotherapy-among-different-molecular-subtypes-of-metastatic-breast-cancer-a-prospective-study","Differential Clinical Outcomes of Palliative Radiotherapy among Different Molecular Subtypes of Metastatic Breast Cancer - A Prospective Study","","A prospective study evaluates how molecular subtypes of metastatic breast cancer influence clinical response to hypofractionated palliative radiotherapy (HPRT). Metastatic breast cancer patients enrolled between December 2021 and September 2022 received HPRT with systemic therapy and were followed for up to 12 months, with molecular subtype, local control, and progression-free survival recorded. Eighty patients were analyzed; local control and PFS differed by Luminal, TNBC, and HER2+ subtypes, with TNBC showing poorest outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/differential-clinical-outcomes-of-palliative-radiotherapy-among-different-molecular-subtypes-of-metastatic-breast-cancer-a-prospective-study/356195/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/differential-clinical-outcomes-of-palliative-radiotherapy-among-different-molecular-subtypes-of-metastatic-breast-cancer-a-prospective-study/356195.png","ImageObject",300,407,{"name":42,"@type":43},"pixelkiddo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study population and radiotherapy approach were used?","Question",{"text":63,"@type":64},"Metastatic breast cancer patients were enrolled from December 2021 to September 2022 and treated with hypofractionated palliative radiotherapy (HPRT). All patients also received systemic therapy and were evaluated through 12 months post-radiotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were molecular subtypes categorized in the study?",{"text":68,"@type":64},"Breast cancers were classified into molecular subtypes including Luminal B, Luminal A, TNBC, and HER2+ based on the molecular profiling described in the article.",{"name":70,"@type":61,"acceptedAnswer":71},"Which molecular subtype showed the poorest outcomes after HPRT?",{"text":72,"@type":64},"TNBC patients performed the poorest, with the study reporting the lowest progression-free survival outcomes compared with Luminal and HER2+ subtypes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356195,1790729397,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","RESEARCH ARTICLE  \n\n| Editorial Proc | ess: Submission:08/14/2025 Acceptance:02/17/2026 Published:03/06/2026 |\n| --- | --- |\n\nDifferential Clinical Outcomes of Palliative Radiotherapy among Different Molecular Subtypes of Metastatic Breast Cancer: A Prospective Study  \nNaveen Thimmaiah 1, Nirupama Naveen2 *, Ayushee Saini3, Uday Krishna4, Mageshraja Kannan5, Tanvir Pasha1, Sridhar Poojar1  \nAbstract  \nBackground: Molecular classification is used to tailor systemic therapy in breast cancer (BC) . However, thereis a paucity of literature correlating the response to radiotherapy with molecular subtypes of metastatic breast cancer (MBC) This prospective study intends to evaluate the differences in clinical outcomes in the different molecular subtypes of MBC to hypofractionated palliative radiotherapy (HPRT) . Methods: MBC patients between December 2021 to September 2022, with Karnofsky Performance status > 70, were enrolled and treated with HPRT. All patients received systemic therapy. All patients were evaluated until 12 months post-radiotherapy. The molecular subtype of BC, local control (LC), and progression-free survival (PFS) were documented. Result: Eighty patients were recruited, with a mean age of 51 ± 10.48 years. Twelve of 80 patients expired, and 16 of 80 patients were lost to follow-up. The molecular subtypes were: Luminal B (37.5%), Luminal A (30%), TNBC (20%) and HER2+ (12.5%) . At 6 months post-RT, 61.5% patients had local control (LC) at their metastatic site, whereas 38.5% had Progressive disease (PD) . At 12 months, 71.1% had LC at the metastatic site, and 28.9% had progression. Local control at 6 months by subtype: Luminal A-83%, Luminal B-60%, HER2+ – 50% and TNBC – 31.2%(p = 0.01) . The median progression-free survival (PFS) of the study group was 6 months (95% CI: 4.78-7.22), with TNBC patients performing the poorest. Conclusion: Luminal subtypes have better local control and progression-free survival post-HPRT compared to TNBC and HER2+ subtypes, which can further be used to stratify radiotherapy fractionation schedules.  \nKeywords: Molecular subtypes-Metastatic Breast Cancer-Palliative Radiotherapy  \nAsian Pac J Cancer Prev, 27 (3), 1029-1035  \nIntroduction  \nBreast cancer is the most common cancer in women, with an estimated global incidence of 2.3 million new cases in 2020, representing 11.7% of all cancers [1] . Metastatic breast cancer (MBC) has been reported in approximately 5% to 25% of patients across various centers in India [2] . The most common initial site of distant spread is bone (51%), followed by lung (17%), brain (16%), and liver (6%) [3] . The remaining 10% of patients present with multiple metastatic sites.  \nMolecular analysis of breast cancers using immunohisto chemistry (IHC) has enabled sub-classification into distinct subtypes. Broadly, these include Luminal Estrogen Receptor (ER)-positive (Luminal A and Luminal B), Human Epidermal Growth Factor Receptor 2 (HER2)-enriched, and Basal-like  \n(triple-negative breast cancer, TNBC) subtypes [4] . Prognostic differences among these subtypes are largely attributed to their varying degrees of radio-sensitivity and biological aggressiveness [5] .  \nEach subtype demonstrates a preferential pattern of metastatic spread. Luminal A (LA) and Luminal B (LB) subtypes are more likely to exhibit bone-only metastases, whereas Basal-like (TNBC) and HER2-positive subtypes have a higher propensity for visceral metastases, particularly to the brain, liver, and lungs [6] . Brain metastases are estimated to occur in 10%–15% of all breast cancer cases with brain involvement, rising to 30% in stage IV disease. Notably, patients with TNBC have a 25%–45% estimated risk of developing brain metastases [7] .  \nOligometastatic breast cancer (OMBC) refers to a subset of MBC characterized by ≤5 metastatic lesions [8] .  \n1Department of Radiation Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India. 2Department of Gynaecological Oncology, Kidwai Memorial In","cbCaidspIHIBkn3V","https://ap.wps.com/l/cbCaidspIHIBkn3V","pdf",462063,"English","# Abstract\n# Introduction\n## Molecular classification and subtype patterns\n## Metastatic spread and oligometastatic disease\n## Rationale for differential radiotherapy response\n# Materials and Methods","[{\"question\":\"What study population and radiotherapy approach were used?\",\"answer\":\"Metastatic breast cancer patients were enrolled from December 2021 to September 2022 and treated with hypofractionated palliative radiotherapy (HPRT). All patients also received systemic therapy and were evaluated through 12 months post-radiotherapy.\"},{\"question\":\"How were molecular subtypes categorized in the study?\",\"answer\":\"Breast cancers were classified into molecular subtypes including Luminal B, Luminal A, TNBC, and HER2+ based on the molecular profiling described in the article.\"},{\"question\":\"Which molecular subtype showed the poorest outcomes after HPRT?\",\"answer\":\"TNBC patients performed the poorest, with the study reporting the lowest progression-free survival outcomes compared with Luminal and HER2+ subtypes.\"}]","Differential Clinical Outcomes of Palliative Radiotherapy among Different Molecular Subtypes of Metastatic Breast Cancer - A Prospective Study | PDF",1790123975,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2f62c813ae8044be88668c1c37a7cea.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2121bc72c87299fea3d3eaea3e308aa.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a61040b6ff9336284720c05bf2c8962b.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5f66c2393b450b7bb82770046a8d8ad.webp",980,1385]